Clinical trials: psoriasis
Psoriasis, Cardiovascular Disease
MIcrovascular dysfuNction In Moderate-severe Psoriasis
Psoriasis, a common chronic inflammatory skin disease affecting approximately 2% of the population, is associated with increased cardiovascular (CV) risk.
- Trial name
- MINIMA (NCT04271540)
- Testing
- Tildrakizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Marcelo F. Di Carli, MD, FACC
Psoriatic Arthritis
Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice
This study is a documentation of effectiveness and safety of Humira in patients with psoriatic arthritis.
- Trial name
- NCT01111240
- Where
- 509 sites in Germany
- Volunteers
- 4,635 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Topical Psoriasis Study for Patients Receiving Biologic Therapy
A two-phase, single center, study of 20 subjects to assess 4 weeks of add-on therapy of Topicort® BID and 12 weeks BID on two consecutive days a week to patients with ≤5% BSA who are receiving biologic therapy for at least 24…
- Trial name
- NCT02983981
- Testing
- Topicort Topical Spray
- Volunteers
- 20 people
- Sponsor
- Psoriasis Treatment Center of Central New Jersey
Plaque Psoriasis
Trial of CF101 to Treat Patients With Psoriasis
Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.
- Trial name
- NCT01265667
- Testing
- CF101
- Where
- 18 sites in United States, Bulgaria and 2 more
- Volunteers
- 293 people
- Sponsor
- Can-Fite BioPharma
Psoriasis
A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis
GSK2981278 is an inverse agonist of retinoic acid receptor-related orphan receptor (ROR) gamma. The aim of this study is to evaluate the safety, tolerability, clinical effect, and systemic exposure potential of topically applied…
- Trial name
- NCT03004846
- Testing
- GSK2981278 ointment, Vehicle ointment
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Plaque Psoriasis
A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)
This Phase 3 study (Study 310) has been designed to determine and compare the efficacy and safety of 122-0551 Foam and Vehicle Foam applied twice daily for two weeks in subjects with plaque psoriasis.
- Trial name
- NCT02742441
- Testing
- 122-0551 Foam, Vehicle Foam
- Where
- 21 sites in United States
- Volunteers
- 409 people
- Sponsor
- Therapeutics, Inc.
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA
A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta
The primary purpose is to assess whether there is transfer of Certolizumab Pegol (CZP) from pregnant women receiving treatment with Cimzia® across the placenta to infants by evaluating the concentration of CZP in the plasma of…
- Conditions
- Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- CRIB (NCT02019602)
- Testing
- Blood sampling from mother, Blood sampling from infant, Blood sampling from umbilical cord
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 37 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Psoriasis
The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis
The purpose of this study is to determine the safety and effectiveness in the treatment of psoriasis on the scalp and on the body.
- Trial name
- NCT01139580
- Testing
- Calcipotriene Foam, Vehicle Foam
- Where
- 26 sites in United States
- Volunteers
- 363 people
- Sponsor
- Stiefel, a GSK Company
Arthritis, Psoriatic, Psoriasis
Study Evaluating the Safety and Efficacy of Etanercept in Patients With Psoriatic Arthritis Treated by Rheumatologists
The purpose of this study is to evaluate the safety and effectiveness of etanercept under usual care settings in patients with PsA treated by rheumatologists.
- Conditions
- Arthritis, Psoriatic, Psoriasis, Skin Diseases, Papulosquamous
- Trial name
- NCT00293722
- Testing
- Etanercept
- Where
- Germany
- Volunteers
- 1,308 people
- Sponsor
- Pfizer
Psoriasis
Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab
This is a phase IV randomized, prospective open label study to asses the efficacy of an extended nurse eduction program in improving adherence to the prescribed treatment regimen in the treatment of moderate to severe psoriasis…
- Trial name
- NCT01435265
- Testing
- Standard nurse education, Additional nurse education
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Wake Forest University Health Sciences
Psoriasis
Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies
The purpose of the study is to demonstrate the safety and efficacy of U0267 in subjects with plaque-type psoriasis.
- Trial name
- NCT00688519
- Testing
- U0267, Vehicle
- Where
- 13 sites in United States
- Volunteers
- 336 people
- Sponsor
- Stiefel, a GSK Company
Plaque Psoriasis
Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis
The purpose of this study is to learn more about the immune response to etanercept produced using a modified process in patients with plaque psoriasis.
- Trial name
- NCT02274792
- Testing
- Etanercept
- Where
- 45 sites in United States, Canada
- Volunteers
- 132 people
- Sponsor
- Amgen
Chronic Stable Plaque Psoriasis
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis
This study will compare the efficacy and safety of DFD-06 Cream to Vehicle Cream for topical treatment of moderate to severe plaque psoriasis after 3, 7, and 14 days of treatment.
- Trial name
- NCT02445807
- Testing
- DFD06-Cream, Vehicle Cream
- Where
- 30 sites in United States
- Volunteers
- 265 people
- Sponsor
- Promius Pharma, LLC
Plaque Psoriasis
Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
The objective of this study is to evaluate the long-term safety of IDP-118 lotion.
- Trial name
- NCT02462083
- Testing
- IDP-118 Lotion
- Where
- 46 sites in United States
- Volunteers
- 555 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
- Trial name
- POETYK-PSO-1 (NCT03624127)
- Testing
- BMS-986165, Apremilast
- Where
- 165 sites in United States, Canada and 9 more
- Volunteers
- 666 people
- Sponsor
- Bristol-Myers Squibb
Psoriatic Arthritis
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.
- Trial name
- SPIRIT-P2 (NCT02349295)
- Testing
- Ixekizumab 80 mg Q4W, Ixekizumab 80 mg Q2W
- Where
- 109 sites in United States, Australia and 8 more
- Volunteers
- 363 people
- Sponsor
- Eli Lilly and Company
Palmoplantaris Pustulosis
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
This study will evaluate whether apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment in Japanese subjects with PPP.
- Trial name
- NCT04057937
- Testing
- Apremilast
- Where
- 22 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Amgen
Rheumatoid Arthritis, Psoriatic Arthritis
Korean Post-marketing Surveillance for Xeljanz
The objective of this study is to identify any problems and questions with respect to the safety and efficacy of Xeljanz during the post-marketing period as required by the regulation of MFDS.
- Trial name
- NCT02984020
- Where
- 49 sites in South Korea
- Volunteers
- 1,041 people
- Sponsor
- Pfizer
Psoriasis, Plaque Psoriasis
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
This Phase 2 study has been designed to investigate the clinical safety and efficacy of EDP1815 and to identify an optimal dose in subjects with mild to moderate psoriasis.
- Trial name
- NCT04603027
- Testing
- EDP1815
- Where
- 29 sites in United States, Hungary and 2 more
- Volunteers
- 249 people
- Sponsor
- Evelo Biosciences, Inc.
Psoriatic Arthritis
AsseSSing Impact in pSoriatic Treatment
Psoriatic arthritis (PsA) is a form of inflammatory arthritis associated with the skin condition psoriasis. A variety of different treatments are used to try to control arthritis and skin psoriasis and management often involves…
- Trial name
- ASSIST (NCT05171270)
- Testing
- Questionnaire
- Where
- 21 sites in France, Germany and 3 more
- Volunteers
- 503 people
- Sponsor
- University of Oxford